KRAS and colorectal cancer: Having again the EGFR inhibitors as a paradigm, this is the case of K-Ras mutations leading to constitutive activation of the Ras/MAPK signaling pathway and mediating both intrinsic or acquired resistance to the anti-EGFR mAb cetuximab in colorectal cancers [13].